ACR DSI shares list of FDA-cleared AI algorithms for medical imaging

Michael Walter | | Health Exec | Precision Medicine

The American College of Radiology (ACR) Data Science Institute (DSI) has created a new resource for radiology researchers: a full list of FDA-cleared AI algorithms related to medical imaging.  

The list includes a wide range of AI models and was designed to save researchers valuable time. The list includes a summary of each algorithm’s manufacturer, intended purpose, FDA product area and more.

“Models range from detecting pneumothorax in chest X-rays to highlighting segments of the brain on MRI,” according to a statement from the ACR. “Several models may increase efficiency by detecting positive findings on images and notifying the radiologist of the suspected findings for further action.”

The full list, published on the ACR DSI website, will be updated regularly.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.